Antibody data
- Antibody Data
- Antigen structure
- References [14]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [4]
- Other assay [10]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 51-2400 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- PTEN Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Reactivity
- Human, Mouse
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 200 µg
- Concentration
- 0.25 mg/mL
- Storage
- -20°C
Submitted references Role of PTEN, PI3K, and mTOR in Triple-Negative Breast Cancer.
The Novel Phosphatase Domain Mutations Q171R and Y65S Switch PTEN from Tumor Suppressor to Oncogene.
EphA2, a possible target of miR-200a, functions through the AKT2 pathway in human lung carcinoma.
Melatonin ameliorates renal fibroblast-myofibroblast transdifferentiation and renal fibrosis through miR-21-5p regulation.
Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer.
mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer.
Immunopathologic Assessment of PTEN Expression.
Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence.
Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity.
Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study.
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients.
Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation.
Growth and molecular profile of lung cancer cells expressing ectopic LKB1: down-regulation of the phosphatidylinositol 3'-phosphate kinase/PTEN pathway.
Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation.
Prvanović M, Nedeljković M, Tanić N, Tomić T, Terzić T, Milovanović Z, Maksimović Z, Tanić N
Life (Basel, Switzerland) 2021 Nov 17;11(11)
Life (Basel, Switzerland) 2021 Nov 17;11(11)
The Novel Phosphatase Domain Mutations Q171R and Y65S Switch PTEN from Tumor Suppressor to Oncogene.
Garrido JAMG, Alcantara KMM, Danac JMC, Serrano FEC, Cutiongco-de la Paz EM, Garcia RL
Cells 2021 Dec 5;10(12)
Cells 2021 Dec 5;10(12)
EphA2, a possible target of miR-200a, functions through the AKT2 pathway in human lung carcinoma.
Tsubochi H, Minegishi K, Goto A, Nakamura R, Matsubara D, Dobashi Y
International journal of clinical and experimental pathology 2020;13(8):2201-2210
International journal of clinical and experimental pathology 2020;13(8):2201-2210
Melatonin ameliorates renal fibroblast-myofibroblast transdifferentiation and renal fibrosis through miR-21-5p regulation.
Li N, Wang Z, Gao F, Lei Y, Li Z
Journal of cellular and molecular medicine 2020 May;24(10):5615-5628
Journal of cellular and molecular medicine 2020 May;24(10):5615-5628
Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer.
Chen J, Guccini I, Di Mitri D, Brina D, Revandkar A, Sarti M, Pasquini E, Alajati A, Pinton S, Losa M, Civenni G, Catapano CV, Sgrignani J, Cavalli A, D'Antuono R, Asara JM, Morandi A, Chiarugi P, Crotti S, Agostini M, Montopoli M, Masgras I, Rasola A, Garcia-Escudero R, Delaleu N, Rinaldi A, Bertoni F, Bono J, Carracedo A, Alimonti A
Nature genetics 2018 Feb;50(2):219-228
Nature genetics 2018 Feb;50(2):219-228
mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer.
Zabala-Letona A, Arruabarrena-Aristorena A, Martín-Martín N, Fernandez-Ruiz S, Sutherland JD, Clasquin M, Tomas-Cortazar J, Jimenez J, Torres I, Quang P, Ximenez-Embun P, Bago R, Ugalde-Olano A, Loizaga-Iriarte A, Lacasa-Viscasillas I, Unda M, Torrano V, Cabrera D, van Liempd SM, Cendon Y, Castro E, Murray S, Revandkar A, Alimonti A, Zhang Y, Barnett A, Lein G, Pirman D, Cortazar AR, Arreal L, Prudkin L, Astobiza I, Valcarcel-Jimenez L, Zuñiga-García P, Fernandez-Dominguez I, Piva M, Caro-Maldonado A, Sánchez-Mosquera P, Castillo-Martín M, Serra V, Beraza N, Gentilella A, Thomas G, Azkargorta M, Elortza F, Farràs R, Olmos D, Efeyan A, Anguita J, Muñoz J, Falcón-Pérez JM, Barrio R, Macarulla T, Mato JM, Martinez-Chantar ML, Cordon-Cardo C, Aransay AM, Marks K, Baselga J, Tabernero J, Nuciforo P, Manning BD, Marjon K, Carracedo A
Nature 2017 Jul 6;547(7661):109-113
Nature 2017 Jul 6;547(7661):109-113
Immunopathologic Assessment of PTEN Expression.
Castillo-Martin M, Thin TH, Collazo Lorduy A, Cordon-Cardo C
Methods in molecular biology (Clifton, N.J.) 2016;1388:23-37
Methods in molecular biology (Clifton, N.J.) 2016;1388:23-37
Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence.
Revandkar A, Perciato ML, Toso A, Alajati A, Chen J, Gerber H, Dimitrov M, Rinaldi A, Delaleu N, Pasquini E, D'Antuono R, Pinton S, Losa M, Gnetti L, Arribas A, Fraering P, Bertoni F, Nepveu A, Alimonti A
Nature communications 2016 Dec 12;7:13719
Nature communications 2016 Dec 12;7:13719
Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity.
Toso A, Revandkar A, Di Mitri D, Guccini I, Proietti M, Sarti M, Pinton S, Zhang J, Kalathur M, Civenni G, Jarrossay D, Montani E, Marini C, Garcia-Escudero R, Scanziani E, Grassi F, Pandolfi PP, Catapano CV, Alimonti A
Cell reports 2014 Oct 9;9(1):75-89
Cell reports 2014 Oct 9;9(1):75-89
Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study.
Zu K, Martin NE, Fiorentino M, Flavin R, Lis RT, Sinnott JA, Finn S, Penney KL, Ma J, Fazli L, Gleave ME, Bismar TA, Stampfer MJ, Pollak MN, Loda M, Mucci LA, Giovannucci E
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2013 Nov;22(11):1984-93
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2013 Nov;22(11):1984-93
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients.
Lotan TL, Gurel B, Sutcliffe S, Esopi D, Liu W, Xu J, Hicks JL, Park BH, Humphreys E, Partin AW, Han M, Netto GJ, Isaacs WB, De Marzo AM
Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Oct 15;17(20):6563-73
Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Oct 15;17(20):6563-73
Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation.
Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM, Sportoletti P, Varmeh S, Egia A, Fedele G, Rameh L, Loda M, Pandolfi PP
Science signaling 2010 Apr 13;3(117):ra29
Science signaling 2010 Apr 13;3(117):ra29
Growth and molecular profile of lung cancer cells expressing ectopic LKB1: down-regulation of the phosphatidylinositol 3'-phosphate kinase/PTEN pathway.
Jimenez AI, Fernandez P, Dominguez O, Dopazo A, Sanchez-Cespedes M
Cancer research 2003 Mar 15;63(6):1382-8
Cancer research 2003 Mar 15;63(6):1382-8
Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation.
Soria JC, Lee HY, Lee JI, Wang L, Issa JP, Kemp BL, Liu DD, Kurie JM, Mao L, Khuri FR
Clinical cancer research : an official journal of the American Association for Cancer Research 2002 May;8(5):1178-84
Clinical cancer research : an official journal of the American Association for Cancer Research 2002 May;8(5):1178-84
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Knockout of PTEN was achieved by CRISPR-Cas9 genome editing using LentiArray™ Lentiviral sgRNA (Product # A32042, Assay ID CRISPR766883_LV) and LentiArray Cas9 Lentivirus (Product # A32064). Western blot analysis of PTEN was performed by loading 30 µg of HeLa Cas9 (Lane 1) andHeLa PTEN KO (Lane 2) whole cell extracts. The samples were electrophoresed using NuPAGE™ Novex™ 4-12% Bis-Tris Protein Gel (Product # NP0322BOX). Resolved proteins were then transferred onto a nitrocellulose membrane (Product # IB23001) by iBlot® 2 Dry Blotting System (Product # IB21001). The blot was probed with Anti-PTEN Polyclonal Antibody (Product # 51-2400, 1:1000 dilution) and Goat anti-Rabbit IgG (H+L) Superclonal™ Recombinant Secondary Antibody, HRP (Product # A27036, 1:5000 dilution) using the iBright FL 1000 (Product # A32752). Chemiluminescent detection was performed using SuperSignal™ West Dura Extended Duration Substrate (Product # 34076). Loss of signal upon CRISPR mediated knockout (KO) using the LentiArray™ CRISPR product line confirms that antibody is specific to PTEN.An uncharacterized band observed around ~130 kDa in both samples.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Human prostate tissue stained with rabbit anti-PTEN antibody (Product # 18-0256).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry analysis of PTEN showing staining in the cytoplasm and nucleus of paraffin-embedded human breast carcinoma (right) compared to a negative control without primary antibody (left). To expose target proteins, antigen retrieval was performed using 10mM sodium citrate (pH 6.0), microwaved for 8-15 min. Following antigen retrieval, tissues were blocked in 3% H2O2-methanol for 15 min at room temperature, washed with ddH2O and PBS, and then probed with a PTEN polyclonal antibody (Product # 51-2400) diluted in 3% BSA-PBS at a dilution of 1:100 overnight at 4°C in a humidified chamber. Tissues were washed extensively in PBST and detection was performed using an HRP-conjugated secondary antibody followed by colorimetric detection using a DAB kit. Tissues were counterstained with hematoxylin and dehydrated with ethanol and xylene to prep for mounting.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry analysis of PTEN showing staining in the cytoplasm of paraffin-embedded human prostate carcinoma (right) compared to a negative control without primary antibody (left). To expose target proteins, antigen retrieval was performed using 10mM sodium citrate (pH 6.0), microwaved for 8-15 min. Following antigen retrieval, tissues were blocked in 3% H2O2-methanol for 15 min at room temperature, washed with ddH2O and PBS, and then probed with a PTEN polyclonal antibody (Product # 51-2400) diluted in 3% BSA-PBS at a dilution of 1:100 overnight at 4°C in a humidified chamber. Tissues were washed extensively in PBST and detection was performed using an HRP-conjugated secondary antibody followed by colorimetric detection using a DAB kit. Tissues were counterstained with hematoxylin and dehydrated with ethanol and xylene to prep for mounting.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry analysis of PTEN showing staining in the cytoplasm and nucleus of paraffin-embedded mouse prostate tissue (right) compared to a negative control without primary antibody (left). To expose target proteins, antigen retrieval was performed using 10mM sodium citrate (pH 6.0), microwaved for 8-15 min. Following antigen retrieval, tissues were blocked in 3% H2O2-methanol for 15 min at room temperature, washed with ddH2O and PBS, and then probed with a PTEN polyclonal antibody (Product # 51-2400) diluted in 3% BSA-PBS at a dilution of 1:100 overnight at 4°C in a humidified chamber. Tissues were washed extensively in PBST and detection was performed using an HRP-conjugated secondary antibody followed by colorimetric detection using a DAB kit. Tissues were counterstained with hematoxylin and dehydrated with ethanol and xylene to prep for mounting.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 4 Melatonin increased the miR-21-5p targets Spry1 and PTEN expression, but not Smurf2 or PDCD4. The levels of Spry1 (A), PTEN (B), Smurf2 (C) and PDCD4 (D) protein expression were examined by Western blot inNRK-49F cells co-treated with TGF-beta1 (2 ng/mL) and 10 umol/L of melatonin for 48 h; n = 6, * P < .01, & P < .05 compared with control group, # P < .01, SS P < .05, compared with TGF-beta1 + Vehicle group. The level of alpha-SMA protein in NRK-49F cells was evaluated by Western blot. NRK-49F cells were transfected with Spry1 siRNA/control siRNA (E) and PTEN siRNA/control siRNA (F), respectively, and then co-cultured with TGF-beta1 (2 ng/mL) with or without 10 umol/L of melatonin for 48 h; n = 6, * P < .01 compared with control group, # P < .01 compared with TGF-beta1 + Vehicle group, P < .01 compared with TGF-beta1 + melatonin + control siRNA
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 5 MiR-21-5p alleviated renoprotective effects of melatonin and inhibited up-regulation of Spry1 and PTEN induced by melatonin in the kidney tissues of unilateral ureteral obstruction (UUO) mice. A, Renal tubular injury was assessed by haematoxylin and eosin (HE) staining (x200). Scale bar = 50 um. B, The deposition of collagen in kidney tissues of UUO rats was determined by Masson''s trichrome staining (x200). Blue (aniline blue) represents collagen fibres; red (acid fuchsin) represents muscle fibres. Scale bar = 50 um. C and D, The statistical analyses of tubulointerstitial damage scores and the degrees of interstitial collagen deposition in different groups. E, RT-PCR analysis of the expression of miR-21-5p in kidneys of mice in different group. F, Western blot analysis of the expression of PTEN and Spry1 in different groups. Bars represent means +- standard deviation (SD) (n = 8). * P < .01 vs the Sham group; # P < .05, SS P < .01 vs the UUO group; Delta P < 0.05, PS P < .01 vs the UUO + Mel + agomir group; Omega P < 0.05, |= P < 0.01 vs the UUO + Mel group. Mel, melatonin; NC, control agomir
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 2 Level of PTEN, PI3K, and mTOR protein expression according to breast cancer subtype. IHC, Immunohistochemistry.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 6 Western blotting to detect PTEN overexpression and Akt phosphorylation in NIH3T3 cells. ( A ) Confirmation of PTEN overexpression in transfected NIH3T3 cells; the empty vector control is shown. ( B ) Akt phosphorylation in NIH3T3 cells. Cells were serum-starved for 24 h before induction of Akt phosphorylation via a brief 5 min treatment with 2 ng/mL EGF, before harvesting protein lysates. ( C ) Densitometric quantification of Akt phosphorylation in ( B ), shown as the ratio of phosphorylated to total Akt. EGF = epithelial growth factor; pTT = pTarget vector; WT = wild-type.